Altimmune, Inc. (NASDAQ:ALT - Get Free Report) shares fell 8.1% on Tuesday after HC Wainwright lowered their price target on the stock from $15.00 to $12.00. HC Wainwright currently has a buy rating on the stock. Altimmune traded as low as $9.38 and last traded at $9.40. 509,332 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 5,962,100 shares. The stock had previously closed at $10.23.
Other analysts have also recently issued reports about the stock. B. Riley restated a "buy" rating and set a $20.00 price target on shares of Altimmune in a research note on Thursday, March 28th. The Goldman Sachs Group initiated coverage on shares of Altimmune in a research note on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price target on the stock.
Read Our Latest Report on Altimmune
Institutional Trading of Altimmune
Several institutional investors and hedge funds have recently bought and sold shares of the company. American International Group Inc. increased its holdings in shares of Altimmune by 6.5% in the 4th quarter. American International Group Inc. now owns 26,268 shares of the company's stock worth $296,000 after buying an additional 1,599 shares during the last quarter. MML Investors Services LLC increased its holdings in shares of Altimmune by 10.7% in the 1st quarter. MML Investors Services LLC now owns 22,140 shares of the company's stock worth $93,000 after buying an additional 2,135 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Altimmune by 18.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 20,396 shares of the company's stock worth $86,000 after buying an additional 3,122 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Altimmune in the 4th quarter worth $35,000. Finally, Credit Suisse AG increased its holdings in shares of Altimmune by 8.5% in the 1st quarter. Credit Suisse AG now owns 41,372 shares of the company's stock worth $175,000 after buying an additional 3,235 shares during the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.
Altimmune Trading Down 8.6 %
The stock's fifty day moving average price is $9.91 and its 200 day moving average price is $6.92. The stock has a market cap of $502.64 million, a P/E ratio of -5.67 and a beta of 0.05.
About Altimmune
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
Read More
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
